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Summary  Transient  ischemic  neurological  deﬁcits  following  intravenous  dipyridamole  admin-
istration  during  pharmacological  cardiac  stress  test  are  seldom  reported,  but  there  can  be
serious vascular  complications.  We  report  a  case  of  a  58-year-old  Caucasian  male  who  developed
expressive  aphasia  after  dipyridamole  infusion  during  an  elective  dipyridamole-technetium  car-
diac stress  test  performed  for  chest  pain.  Computed  tomography  angiogram  of  the  neck  revealed
a known  total  occlusion  of  the  right  internal  carotid  artery  and  50%  stenosis  of  the  left  internal
carotid artery.  The  patient’s  aphasia  spontaneously  resolved  within  24  h.In this  paper,  we  report  a  unique  case  in  which  the  administration  of  intravenous  dipyridamole
precipitated  transient  ischemic  attack  in  a  patient  with  stable  asymptomatic  bilateral  carotid
artery disease  and  prior  carotid  endarterectomy.  We  also  discuss  the  intracerebral  vascular
steal phenomenon  as  a  possible  pathophysiological  mechanism  in  this  patient.




Dipyridamole  has  been  widely  used  to  perform  pharmacolog-
ical  cardiac  stress  tests  in  the  evaluation  of  coronary  artery
disease.  The  safety  of  dipyridamole  use  in  nuclear  perfusion
cardiac  imaging  has  been  well  documented  in  the  literature
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ccident  (CVA)  have  been  suggested  as  theoretical  compli-
ations  of  intravenous  dipyridamole,  but  cases  documenting
heir  occurrence  are  seldom  reported.  In  this  paper,  we
eport  a  unique  case  in  which  the  administration  of  intra-
enous  dipyridamole  for  technetium-99m  sestamibi  cardiac
tress  testing  precipitated  TIA  in  a  patient  with  stable,
symptomatic  bilateral  carotid  artery  disease  and  prior
arotid  endarterectomy.  We  also  discuss  the  intracerebral
ascular  steal  phenomenon  as  a  possible  pathophysiological
echanism  in  this  patient.













































































monitoring  was  104/70  mmHg  which  makes  vasodilator-
related  hypotension  an  unlikely  cause  in  our  patient.126  
ase report
 58-year-old  Caucasian  male  with  coronary  artery  disease
tatus  post  coronary  artery  bypass  grafting  was  scheduled  for
ipyridamole  nuclear  perfusion  cardiac  imaging  for  evalua-
ion  of  chest  pain.  His  past  medical  history  was  signiﬁcant  for
ight  carotid  endarterectomy  performed  more  than  10  years
rior,  a  45  pack-year  history  of  smoking,  paroxysmal  atrial
brillation,  peripheral  arterial  disease,  and  hyperlipidemia.
here  was  no  prior  history  of  stroke.  He  was  receiving
oumadin  for  his  paroxysmal  atrial  ﬁbrillation  and  clopido-
rel  for  coronary  artery  disease;  on  the  day  of  his  stress
est,  his  prothrombin  time  was  17.2  s  and  his  international
ormalized  ratio  (INR)  1.9.
A dipyridamole  technetium-99m  sestamibi  cardiac  stress
est  was  performed  using  a  standard  protocol.  At  the  end  of
he  dipyridamole  infusion  over  5  min,  the  patient  developed
xpressive  aphasia  and  associated  generalized  weakness
ithout  any  focal  motor  deﬁcits.  His  saturation  on  pulse
ximetry  was  95%  on  2  liters  nasal  cannula.  Blood  pressure
as  recorded  at  126/80  mmHg  during  the  episode.  Elec-
rocardiogram  showed  sinus  rhythm  with  a  heart  rate  of
4/min.  Intravenous  aminophylline  was  administered  imme-
iately,  which  improved  the  generalized  weakness,  but  not
is  expressive  aphasia.  His  National  Institutes  of  Health
troke  scale  score  was  3.  He  was  transferred  to  the  emer-
ency  department  for  evaluation  of  his  acute  stroke.  During
his  period,  his  vital  signs  remained  stable.  Cardiac  and
espiratory examinations  were  unremarkable.
In  the  emergency  department  his  laboratory  tests  includ-
ng  basic  metabolic  panel  and  complete  blood  count  were
ithin  normal  limits.  An  electrocardiogram  again  showed
ormal  sinus  rhythm,  with  a  heart  rate  of  76/min.  Non-
ontrast  computed  tomography  (CT)  scan  of  the  brain  per
troke  protocol  was  negative  for  intracranial  bleed.  CT
ngiogram  of  the  neck  revealed  total  occlusion  of  the  right
nternal  carotid  artery  and  50%  stenosis  of  the  left  internal
arotid  artery,  consistent  with  results  of  prior  imaging.  Given
he  near  therapeutic  INR  (1.9),  no  further  anticoagulation  or
hrombolytics  were  considered.  His  aphasia  spontaneously
esolved  within  2—3  h  without  any  further  intervention.  He
as  discharged  home  with  no  further  neurological  deﬁcit  or
omplication.
iscussion
ipyridamole  is  one  of  the  most  common  pharmacolog-
cal  stress  agents  used  in  cardiac  nuclear  imaging,  for
he  evaluation  of  coronary  artery  disease.  Dipyridamole,
r  2,2′,2′′,2′ ′ ′-[(4,8-dipiperidinopyrimido[5,4-d] pyrimidine-
,6-diyl)  dinitrilo]-tetraethanol  is  a  phosphodiesterase
nhibitor.  It  is  highly  protein  bound  and  metabolized  by  the
iver.  Dipyridamole  blocks  uptake  and  metabolism  of  adeno-
ine  by  vascular  endothelial  cells  leading  to  dilatation  of  the
istal  vascular  beds.  However,  the  hyperemic  response  in  the
istal  beds  of  stenosed  arteries  is  attenuated.  Thus,  as  ﬂow
ncreases  with  dipyridamole,  heterogeneity  between  normal
nd  stenosed  arteries  is  then  exaggerated.  In  the  coronary
rteries,  the  ‘‘steal’’  phenomenon  facilitates  identiﬁcation
f  coronary  artery  disease.  The  vasodilator  effects  also
ontribute  to  the  common  side  effects  of  hypotension
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reported  in  4.6%  of  patients),  headache,  and  dizziness  (12%)
2].
Neurological  adverse  effects  of  intravenous  dipyridamole
ave  seldom  been  reported  in  the  literature  although  TIA
nd  cerebrovascular  accidents  are  theoretical  complica-
ions  [1,3]. Previous  case  reports  have  hypothesized  that
n  intracerebral  steal  phenomenon  precipitated  TIAs  by
ffecting  either  large  proximal  or  smaller  branch  vessels
4—6].  One  study  speciﬁcally  addressed  the  safety  of  dipyri-
amole  in  patients  with  cerebrovascular  disease  [3].  Only
ne  TIA  occurred  among  400  patients,  and  that  was  noted
n  a  patient  with  severe  hypertension  and  a  normal  carotid
oppler.  Although  these  results  are  reassuring,  the  study
xcluded  patients  with  prior  carotid  endarterectomy.  There-
ore,  our  case  is  unique.
We  investigated  alternative  causes  for  TIA  in  our  patient.
e  was  adequately  anticoagulated,  making  cardioembolic
IA  secondary  to  paroxysmal  atrial  ﬁbrillation  unlikely.  He
id  not  have  an  intracerebral  hemorrhage  on  CT  or  unsta-
le  carotid  plaque  on  CT  angiogram.  He  did  not  develop  an
rrhythmia,  nor  peripheral  hemodynamic  instability,  during
ardiac  testing.  His  lowest  blood  pressure  during  continuousigure  1  Computed  tomography  angiogram  of  head  and  neck:
rrow  (A)  showing  total  occlusion  of  right  internal  carotid  artery.
rrow (B)  showing  50%  stenosis  of  left  internal  carotid  artery.































[Figure  2  Computed  tomography  angiogram  of  head  and  neck:
arrow  showing  signiﬁcant  right  vertebral  artery  stenosis.
In  the  absence  of  other  etiologies,  we  hypothesize  that
our  patient  developed  a  transient  intracerebral  steal  phe-
nomenon  secondary  to  dipyridamole  infusion,  which  in  turn
precipitated  his  neurological  symptoms.  His  right  internal
carotid  artery  was  chronically  and  completely  occluded  fol-
lowing  a  remote  endarterectomy  (Fig.  1),  thereby  diverting
intracerebral  perfusion  to  the  left  internal  carotid  and  ver-
tebrobasilar  arteries  and  their  collaterals.  He  had  developed
stenosis  of  his  left  internal  carotid  artery  (50%)  and  right
vertebral  artery  based  on  CT  angiography  (Fig.  2),  further
reducing  cerebral  blood  ﬂow.  Magnetic  resonance  imaging
(MRI)  of  the  brain  was  considered  at  this  point  but  was
deferred  due  to  the  unknown  nature  of  the  patient’s  coro-
nary  stent  at  the  time  of  admission.  Since  the  patient’s
symptoms  resolved  within  24  h,  MRI  of  the  brain  was  not  per-
formed.  We  hypothesize  that  dipyridamole  infusion  resulted
in  vasodilatation  of  both  his  external  carotid  arteries  and
left  vertebral  artery,  while  the  caliber  of  the  atheroscle-
rotic  internal  carotid  arteries  and  right  vertebral  artery
remained  unchanged  (Figs.  1  and  2).  These  changes  in
vascular  tone  could  have  created  a  cerebrovascular  steal
phenomenon  with  redistribution  of  blood  ﬂow  away  from
the  left  internal  carotid  artery  system.  Compounding  these
changes,  autoregulation  of  blood  ﬂow  distal  to  stenosed
arteries  was  likely  impaired,  as  shown  previously  by  White
[
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nd Markus  [7].  Together,  these  changes  could  cause  hypop-
rfusion  of  Broca’s  area  and  associated  expressive  aphasia.
s  dipyridamole  levels  dropped  and  its  effects  receded,
erebral  blood  ﬂow  returned  to  baseline  with  resolution
f  the  aphasia.  The  half  life  of  dipyridamole  for  activating
he  -receptors  is  40  min  and  the  -receptors  is  10  h.  Thus,
se  of  adenosine  (half  life  less  than  10  s)  or  regadenoson
half  life  of  2  h)  that  have  much  shorter  half  lives,  would
e  expected  to  have  a  lesser  effect  on  a  steal  phenomenon
ompared  to  dipyridamole  [8].
onclusion
ntravenous  dipyridamole  is  frequently  used  in  nuclear  per-
usion  cardiac  imaging.  Its  safety  proﬁle  is  excellent  in
ost  patients.  However,  patients  with  pre-existing  cere-
rovascular  stenosis  may  be  at  greater  risk  for  neurological
omplications  due  to  cerebrovascular  steal  phenomenon  and
mpaired  cerebral  autoregulation.  We  suggest  that  addi-
ional  caution  should  be  taken  among  such  patients,  with
rompt  institution  of  measures  to  increase  cerebral  blood
ow  if  symptoms  of  TIA  develop.
cknowledgments
he  abstract  was  accepted  and  presented  at  the  Society  of
ascular  Medicine  22nd  annual  scientiﬁc  meeting  May  2011
t  Boston,  MA,  USA.
eferences
1] Lette J, Tatum J, Fraser S, Miller D, Waters D, Heller G, et al.
Safety of dipyridamole testing in 73,806 patients: The Multicen-
ter Dipyridamole Safety Study. J Nucl Cardiol 1995;2:3—17.
2] Ranhosky A, Kempthorne-Rawson J. Intravenous Dipyridamole
Thallium Imaging Study Group. The safety of intravenous dipyri-
damole thallium myocardial perfusion imaging. Circulation
1990;81:1205—9.
3] Lette J, Carini G, Tatum JL, Paquet N, Bisson G, Picard M, et al.
Safety of dipyridamole testing in patients with cerbrovascular
disease. Am J Cardiol 1995;75:535—7.
4] Whiting Jr JH, Datz FL, Gabor FV, Jones SR, Morton KA.
Cerebrovascular accident associated withdipyridamolethallium-
201 myocardial imaging: case report. J Nucl Med 1993;34:
128—30.
5] Schechter D, Bocher M, Berlatzky Y, Anner H, Argov Z, Beer G,
et al. Transient neurological events during dipyridamole stress
test: an arterial steal phenomenon? J Nucl Med 1994;35:1802—4.
6] Pounds BK, Moore WH, Ladwig EJ. Dipyridamole thallium imag-
ing. J Nucl Med Technol 1990;18:165—75.7] White RP, Markus HS. Impaired dynamic cerebral autoregulation
in carotid artery stenosis. Stroke 1997;28:1340—4.
8] Dipyridamole. Drug Information Online.
http://www.drugs.com/mtm/dipyridamole.html.
